Aristada

Schizophrenia
Treatment
1 FDA approval
20 Active Studies for Aristada

What is Aristada

Aripiprazole lauroxilThe Generic name of this drug
Treatment SummaryAripiprazole lauroxil is a medication used to treat schizophrenia in adults. It works by reducing the activity of certain receptors in the brain that are linked to schizophrenia. It was approved by the FDA in 2015 and can be given as an injection or in combination with an oral dose of aripiprazole. Aripiprazole lauroxil has been found to be effective and safe, and can reduce the frequency of dosing to improve patient adherence.
Aristadais the brand name
image of different drug pills on a surface
Aristada Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aristada
Aripiprazole lauroxil
2015
5

Approved as Treatment by the FDA

Aripiprazole lauroxil, otherwise known as Aristada, is approved by the FDA for 1 uses like Schizophrenia .
Schizophrenia
Used to treat Schizophrenia in combination with Aripiprazole

Effectiveness

How Aristada Affects PatientsAripiprazole is a drug that helps to improve the symptoms of schizophrenia and works by affecting the dopamine-related pathways in the body. It has been shown to have little impact on sexual function or breast milk production.
How Aristada works in the bodyAripiprazole works on dopamine and serotonin receptors in the brain to reduce the symptoms of schizophrenia. It acts as a partial agonist at dopamine and serotonin receptors in the limbic system, reducing the positive symptoms. It also acts as a functional antagonist in the mesolimbic dopamine pathway, which helps reduce the intensity of these symptoms. At serotonin receptors, it functions as an antagonist, decreasing negative symptoms and cognitive impairment. Aripiprazole also blocks alpha-1 adrenergic receptors, which can lead to low blood pressure, and histamine H1 receptors, which can cause drowsiness.

When to interrupt dosage

The dosage of Aristada is subject to the perceived affliction. The amount of dosage is contingent upon the method of delivery noted in the table below.
Condition
Dosage
Administration
Schizophrenia
, 441.0 mg/mL, 662.0 mg/mL, 882.0 mg/mL, 1064.0 mg/mL, 675.0 mg/mL
, Intramuscular, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular

Warnings

Aristada Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Aristada.
Common Aristada Drug Interactions
Drug Name
Risk Level
Description
Alfuzosin
Major
Aripiprazole lauroxil may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Aripiprazole lauroxil may increase the antipsychotic activities of Amisulpride.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Aripiprazole lauroxil.
Azelastine
Major
Aripiprazole lauroxil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Aripiprazole lauroxil.
Aristada Toxicity & Overdose RiskTests have found that the lethal dose of aripiprazole in rats is greater than 60mg. For female and male rats, the oral lethal dose was 705mg/kg and 965mg/kg respectively. The maximum recommended daily dose of aripiprazole is 1260mg, but an overdose of this can cause vomiting, drowsiness, trembling, acidosis, aggression, increased liver enzymes, irregular heartbeat, confusion, seizures, low potassium levels, loss of consciousness, abnormal electrical activity in the heart, aspiration pneumonia, stopped breathing, prolonged QRS complex, prolonged QT interval, and rapid heartbeat. A
image of a doctor in a lab doing drug, clinical research

Aristada Novel Uses: Which Conditions Have a Clinical Trial Featuring Aristada?

At present, 170 active studies are investigating the potential of Aristada to treat Schizophrenia.
Condition
Clinical Trials
Trial Phases
Schizophrenia
106 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Aristada Reviews: What are patients saying about Aristada?

4.3Patient Review
10/25/2017
Aristada for Schizophrenia
This is the most effective medication I've found for my auditory hallucinations. It's not a cure, but it definitely makes them more manageable and less disruptive to my life.
1Patient Review
5/14/2022
Aristada for Schizophrenia
If you're experiencing a severe allergic reaction to this drug, Benadryl may help lessen the symptoms. You can either ask your doctor for an IV or get a shot of it intramuscularly. If you still have to stay on the injection and are allergic to aripiprazole lauroxil, Benadryl and Claritin may be of benefit to you.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aristada

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Aristada an antipsychotic?

"Both Aristada and Abilify Maintena are antipsychotic drugs."

Answered by AI

How often is Aristada injection given?

"The recommended dose of ARISTADA is 441 mg, 662 mg, or 882 mg administered monthly, 882 mg dose every 6 weeks, or 1064 mg dose every 2 months."

Answered by AI

What is the drug Aristada used for?

"It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. Aripiprazole belongs to a class of drugs called atypical antipsychotics.

Extended-release aripiprazole injection is used as a treatment for schizophrenia, a mental/mood disorder. The medication can help patients by decreasing hallucinations and increasing concentration levels. It also allows the individual to think more clearly, feel less nervous, and take a more active role in everyday life. Aripiprazole belongs to a class of drugs known as atypical antipsychotics."

Answered by AI

What is the difference between Aristada and Abilify?

"Aristada is currently only FDA-approved to treat schizophrenia, but Abilify Maintena is approved to treat both bipolar I disorder and schizophrenia. Abilify Maintena is typically given as a monthly injection, while Aristada can be given as infrequently as every two months."

Answered by AI

Clinical Trials for Aristada

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Woodland International Research Group /ID# 275747 (+4 Sites)ABBVIE INC.AbbVie
Have you considered Aristada clinical trials? We made a collection of clinical trials featuring Aristada, we think they might fit your search criteria.Go to Trials
Have you considered Aristada clinical trials? We made a collection of clinical trials featuring Aristada, we think they might fit your search criteria.Go to Trials
Image of Clinical Site in Richmond, United States.

Xanomeline/Trospium for Schizophrenia

18 - 40
All Sexes
Richmond, TX
This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness. Participants will be followed for 24 weeks with scheduled assessments conducted by centralized raters, local mental health professionals and self-assessments completed by patients. Recruitment will be based on insufficient efficacy of previous antipsychotic or due to dissatisfaction with treatment as a result of unacceptable side effects on previous antipsychotic/patient choice, with approximately 50% for each enrollment criteria. Participants who present with both insufficient efficacy and unacceptable side effects will be considered as belonging to the insufficient efficacy subgroup. Treatment and assessments will be identical for the 2 groups. Primary outcome for participants enrolled will be improvement in overall treatment satisfaction as measured by the MSQ.
Phase 4
Waitlist Available
Clinical SiteBristol-Myers Squibb
Have you considered Aristada clinical trials? We made a collection of clinical trials featuring Aristada, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security